
A New Glaucoma Procedure Uses Donor Tissue to Keep the Eye’s Drainage Canal Open — First Human Results Are In
This audio article is from VisualFieldTest.com.
Read the full article here: https://visualfieldtest.com/en/a-new-glaucoma-procedure-uses-donor-tissue-to-keep-the-eye-s-drainage-canal-open-first-human-results-are-in
Test your visual field online: https://visualfieldtest.com
Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support
Excerpt:
A New Glaucoma Procedure Uses Donor Tissue to Keep the Eye’s Drainage Canal Open — First Human Results Are In Short answer: The first results are encouraging, but they do not yet show that donor tissue makes canaloplasty more durable. The reported 52-eye study has no published full paper, no control group, and only six months of follow-up. Because the procedure was combined with cataract surgery, some—and possibly a substantial part—of the pressure drop may have come from cataract removal rather than the allograft. The idea is plausible: open Schlemm’s canal, then support it with donor tissue. But the key claim—that this support prevents clinically important canal recoil and improves lasting pressure control—still needs a randomized comparison. Evidence reviewed through October 16, 2026. What the first 52-eye results show On October 8, 2026, Iantrek announced preliminary six-month results from a first-in-human, single-center observational study of bio-reinforced canaloplasty combined with cataract surgery. The company reported outcomes for 52 treated eyes. The full study report was not published with the announcement; the data were described as “on file” and subject to further analysis. (Iantrek’s October 8 announcement, Ophthalmology Management’s report) For the full table, please open this article on visualfieldtest.com. The 14.1 figure is calculated, not separately published: 22.4 × (1 − 0.372) = 14.07. Because the baseline and percentage are rounded, the exact study mean might differ slightly. The medication calculation is also approximate: a 49.1% reduction from 1.2 medications implies a reduction of about 0.59, leaving an average of about 0.61. These are the figures in the company announcement, not independently audited results. “No serious adverse events” does not mean there were no minor events, and a group of 52 eyes followed for six months cannot rule out uncommon complications or late problems. Important study details are not yet public The announcement does not provide enough information to establish several facts requested for a proper clinical assessment: Glaucoma severity and subtype: Not reported for the 52-eye cohort. Patient age: Not reported. Previous selective laser trabeculoplasty or minimally invasive glaucoma surgery: Not reported. Detailed inclusion criteria: Not reported. Medication washout before baseline pressure measurement: Not reported. This matters: a pressure measured after stopping drops is not directly comparable with one measured while patients are taking them. Cataract surgery: The study is described as bio-reinforced canaloplasty performed with cataract surgery. That implies the reported 52 eyes had combined surgery, but the press release does not provide a patient-by-patient study table. Exact surgical steps: The type of dilation, how much of the canal was treated, and the precise graft-placement steps are not reported. Allograft length and exact placement extent: Not reported for AlloSpan. Postoperative eye-drop regimen: Not reported. A separate, ongoing study called BOOST is registered as an observational study of bio-reinforced canaloplasty. Its registry describes placing minimally manipulated, homologous-use scleral allograft tissue in the wall region of Schlemm’s canal after canaloplasty. It targets 300 participants and plans two years of follow-up; it is not a randomized comparison of graft versus no graft. BOOST’s eligibility rules should not be assumed to describe the earlier 52-eye study. (BOOST study record) What “bio-reinforced canaloplasty” means The eye continuously produces clear fluid called aqueous humor. It normally drains through the trabecular meshwork, into Schlemm’s canal, and then through collector channels toward the veins around the eye. In open-angle glaucoma, pressure can rise when this drainage system does not carry fluid away efficiently. Conventional canaloplasty In conventional canaloplasty, a surgeon uses an instrument to enter and dilate Schlemm’s canal, commonly by delivering a viscoelastic fluid. Some versions also place a tensioning suture around the canal; other, newer ab-interno procedures do not. The goal is to stretch the canal and improve flow through the eye’s existing drainage route. The proposed AlloSpan approach Bio-reinforced canaloplasty adds another step: after dilating the canal, the surgeon places homologous donor scleral tissue in the canal-wall region to provide structural support. Public descriptions also characterize the platform as nitinol-guided and trabecular-meshwork-sparing, but the detailed steps used in the 52-eye study have not been published. (BOOST study record, Iantrek’s AlloSpan introduction) The concept is therefore: Conventional approach: Dilate the canal; hope the improved opening and flow persist. Bio-reinforced approach: Dilate the canal, then add a biological scaffold intended to support its structure. The word “reinforced” describes the intended mechanical role. It does not yet establish that the canal stays wider, that collector-channel flow improves, or that pressure control lasts longer. Does Schlemm’s canal actually collapse or recoil after canaloplasty? Canal narrowing is a real feature of eye anatomy. But current evidence does not establish that post-surgical recoil is a major cause of conventional canaloplasty losing effectiveness. What imaging and tissue studies show Anterior-segment optical coherence tomography studies have found that Schlemm’s canal can be larger after canaloplasty. One study documented increased canal dimensions during the first few months after surgery; another examined canal and trabecular-meshwork changes one year after combined cataract surgery and canaloplasty. Those studies support the idea that surgery changes the canal’s anatomy. They do not show that later pressure rises are caused by canal recoil, or that a graft prevents such rises. (Three-month imaging study, one-year phacocanaloplasty imaging study) Laboratory and histological work also shows that the trabecular meshwork can bow toward—and narrow—the canal as pressure changes. But Schlemm’s canal is not simply an empty pipe. Its walls, internal supports, collector-channel openings, and surrounding tissues all respond to pressure. (Histopathological review of trabecular surgery, study of Schlemm’s canal and collector-channel anatomy) Conventional canaloplasty can last for years without an allograft Longer-term clinical results show that conventional canaloplasty can retain meaningful effects, although the evidence is mostly nonrandomized and outcomes vary. In a multicenter three-year study, the overall mean pressure was 15.2, while eyes having combined cataract surgery and canaloplasty averaged 13.6. In a separate ten-year observational study, mean pressure at ten years was 15.9 after canaloplasty alone and 14.2 after combined cataract surgery and canaloplasty. Medication use rose over time in some groups, suggesting that pressure lowering and medication reduction are not the same thing. (Three-year canaloplasty results, ten-year canaloplasty results) These studies do not prove that canal anatomy never changes after surgery. They do show that a donor scaffold is not already known to be necessary for long-term canaloplasty benefit. A key missing link is evidence that patients whose canal later narrows are the same patients whose pressure control fails. A larger canal may not solve all drainage problems Even with a wider canal, fluid must still pass through the collector channels and other downstream tissues. Research suggests a substantial share of resistance can lie beyond Schlemm’s canal, in the collector-channel and venous pathways. So keeping the canal open could help, but it cannot necessarily fix blocked or poorly functioning downstream drainage. (Review of Schlemm’s canal procedures and outflow resistance) How much of the pressure drop could cataract surgery explain? This is the study’s biggest interpretive problem. AlloSpan was not tested against cataract surgery alone or against ordinary canaloplasty. Cataract removal can lower pressure on its own, especially when the pressure before surgery is high. In the randomized HORIZON trial, patients with open-angle glaucoma had a medication-washout baseline mean pressure of about 24.5. At 24 months, the cataract-surgery-only group had an average pressure decrease of 5.3, about 22% of baseline. In an Ocular Hypertension Treatment Study analysis, cataract surgery was associated with a pressure decrease from a higher baseline, but the effect differed according to baseline pressure and medication use. (HORIZON trial report, Ocular Hypertension Treatment Study cataract analysis, analysis of cataract surgery in treated patients) The AlloSpan announcement implies an overall decrease of about 8.3—from 22.4 to about 14.1. As a rough comparison: If the 22.4 baseline was measured after medication washout, cataract-only results in a similar pressure range suggest cataract surgery might explain around 5 millimeters of mercury, or about 22 percentage points of the reported reduction. If baseline was measured while patients were using their usual drops, the cataract-only contribution might be closer
Altri episodi di "Glaucoma, Vision & Longevity: Supplements & Science"



Non perdere nemmeno un episodio di “Glaucoma, Vision & Longevity: Supplements & Science”. Iscriviti all'app gratuita GetPodcast.








